Log in to search using one of your social media accounts:

 

LIFE Worldwide Newsletter published
Welcome to LIFE's (Leading International Fungal Education) July newsletter. Please  follow this link.Leading feature: Randomised trial establishes amphotericin B as best therapy forTalaromyces marneffei in HIVOther featured news items include:Updates (Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - July 20, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

ram1 gene, encoding a subunit of farnesyltransferase, contributes to growth, antifungal susceptibility to amphotericin B of Aspergillus fumigatus.
(Source: The Aspergillus Website - updates)
Source: The Aspergillus Website - updates - June 20, 2017 Category: Respiratory Medicine Authors: GAtherton Source Type: news

iCo Strategic Reorganization
VANCOUVER , Jan. 18, 2016 (Healthcare Sales & Marketing Network) - iCo Therapeutics Inc. ("iCo" or "the Company") (ICO.V) (ICOTF), today announced that effective immediately, in an effort to preserve its asset base and maximize sharehol... BiopharmaceuticalsiCo Therapeutics, Oral Amphotericin B (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 18, 2016 Category: Pharmaceuticals Source Type: news

Guideline Updates: Adult & Adolescent OI Guideline
Authors of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents have recently released updates to the following sections: HPV - This update provides new recommendations regarding the cervical cancer screening interval for HIV-positive women after 3 consecutive normal Pap tests, and the use of HPV co-testing among HIV-positive  women>30 years of age. It additionally includes recommendations regarding the use of 9-valent HPV vaccine among HIV-positive females and males ages 9-26 to prevent HPV infection. HSV - This update provides new information rega...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 25, 2015 Category: Infectious Diseases Source Type: news

Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
Co-Inventor of the Company's Proprietary Lipid-Crystal Nano-Particle Cochleate Technology Joins Management Sept. 1 BEDMINSTER, N.J., Sept. 1, 2015 -- (Healthcare Sales & Marketing Network) -- Matinas BioPharma Holdings, Inc. (MTNB), a clinical-stage bio... Biopharmaceuticals, Drug Delivery, PersonnelMatinas BioPharma, nano-particle, amphotericin B (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 1, 2015 Category: Pharmaceuticals Source Type: news

CHMP Backs Antifungal Isavuconazole (Cresemba)CHMP Backs Antifungal Isavuconazole (Cresemba)
The triazole antifungal is indicated for treatment of adults with invasive aspergillosis and mucormycosis in patients for whom amphotericin B is not appropriate. Orphan Drug Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 29, 2015 Category: Consumer Health News Tags: Infectious Diseases News Alert Source Type: news

Antifungal compounds that evade resistance reported in Nature Chemistry Biology
(Pure Communications Inc.) Antifungal drug discovery progress was reported by the founder of REVOLUTION Medicines founder. Molecules derived from natural product amphotericin B, used as a highly effective treatment for serious fungal infections but is often accompanied by serious side effects, were active against fungal pathogens that cause life-threatening human diseases, effective in treating a rodent model of systemic yeast infections, significantly less toxic to human cells, and unlike many antifungals used today, evaded emergence of drug resistance. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 1, 2015 Category: Infectious Diseases Source Type: news

South Africa: Life-Saving Aids Medicine Out of Stock in Gauteng
[GroundUp]Hospitals throughout Gauteng ran out of essential medicines in recent weeks, including a life-saving drug for people with AIDS called amphotericin B. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - December 9, 2014 Category: Infectious Diseases Source Type: news

No quality control for life-saving generic drugs, government apathetic
A case in point is a life-saving drug, Liposomal Amphotericin B, which is used to treat fungal infections in critically-ill patients. (Source: The Economic Times)
Source: The Economic Times - September 16, 2014 Category: Consumer Health News Source Type: news

Why Does Hypokalemia Happen With Amphotericin B?Why Does Hypokalemia Happen With Amphotericin B?
Why does hypokalemia occur in patients receiving amphotericin B, and how can it be managed? Medscape Pharmacists (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 27, 2014 Category: Drugs & Pharmacology Tags: Pharmacist Ask the Expert Source Type: news

Fungus-fighting drug may make mild flu meaner
(Cell Press) Mice given a drug commonly used in patients to fight systemic fungal infections more often succumb to what would otherwise be a mild case of the flu. The evidence reported in the Cell Press journal Cell Reports on Nov. 21 shows that the drug called amphotericin B, which has an estimated $330 million in sales around the world each year, can render a protein important for antiviral defense ineffective in both cells and mice. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 21, 2013 Category: Infectious Diseases Source Type: news

Leishmaniasis treatment doses and side effects may be dramatically reduced by new discovery
The Amphotericin B (AmB) is the main active ingredient in the most effective drug used to treat leishmaniasis, a disease which in the Western world mainly affects dogs, but in developing countries affects over 12 million people, with more than 70,000 deaths per year. The cost of treating humans with AmB surpasses $5,000 per patient, the treatment is extensive (2-hour sessions every day during 21 days), and the side effects are frequent and many times patients must be hospitalised... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 7, 2013 Category: Consumer Health News Tags: Tropical Diseases Source Type: news

Mucor velutinosus Central-Line-Associated Bloodstream Infection
We present the first reported case of a central-line-associated bloodstream infection caused by this fungus. The patient had a favorable outcome following removal of her central line and subsequent treatment with liposomal amphotericin B. (Source: Clinical Microbiology Newsletter)
Source: Clinical Microbiology Newsletter - November 1, 2013 Category: Microbiology Authors: Amanda Wilmer, Alissa Wright, Victor Leung, Miguel Imperial, Mark W. Hull, Yazdan Mirzanejad, Marc G. Romney Source Type: news

Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration.
Malone ME, Corrigan OI, Kavanagh PV, Gowing C, Donnelly M, D'Arcy DM. (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - August 23, 2013 Category: Respiratory Medicine Source Type: news

Amphotericin B+ and voriconazole+echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.
Antimicrob Agents Chemother. 2013 Jul 15. [Epub ahead of print] (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - August 14, 2013 Category: Respiratory Medicine Source Type: news

WHO reinstates important drugs amphotericin B and flucytosine after pressure from leading expert
A Manchester doctor believes the lives of tens of thousands of people worldwide who develop a deadly type of fungal meningitis could now be saved thanks to a U-turn by the World Health Organisation (WHO). Professor David Denning, who is recognised as an international expert in infectious and fungal diseases, has campaigned with others to have two drugs reinstated on the Essential Medicines List following a definitive trial from Vietnam... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 8, 2013 Category: Consumer Health News Tags: Regulatory Affairs / Drug Approvals Source Type: news

Safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia: a prospective phase II single-center study
Annino L, Chierichini A, Anaclerico B, Finolezzi E, Norata M, Cortese S, Cassetta MI, Fallani S, Novelli A, Girmenia C (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - April 15, 2013 Category: Respiratory Medicine Source Type: news

High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia
Lewis RE, Albert NP, Liao G, Wang W, Prince RA, Kontoyiannis DP (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - April 15, 2013 Category: Respiratory Medicine Source Type: news

Combo Defeats Fungal Meningitis in HIV (CME/CE)
(MedPage Today) -- Induction therapy with combined amphotericin B and flucytosine improved survival in HIV-positive patients with cryptococcal meningitis, a randomized trial determined. (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - April 3, 2013 Category: Consumer Health News Source Type: news

Treatment of Experimental Aspergillosis with Amphotericin B
JOHN H. EVANS a n d ROGER D. BAKER (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 27, 2013 Category: Respiratory Medicine Source Type: news

Hepatosplenic fungal infection: CT and pathologic evaluation after treatment with liposomal amphotericin B
Shirkhoda A, Lopez-Berestein G, Holbert JM, Luna MA (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 27, 2013 Category: Respiratory Medicine Source Type: news

The changing epidemiology of fungal infections: are the lipid-forms of amphotericin B an advance?
Herbrecht R (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 25, 2013 Category: Respiratory Medicine Source Type: news

Amphotericin B-induced myelopathy
Carnevale NT, Galgiani JN, Stevens DA, Herrick MK, Langston JW (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 12, 2013 Category: Respiratory Medicine Source Type: news

Amphotericin B nasal spray as prophylaxis against aspergillosis in patients with neutropenia
Meunier-Carpentier F, Snoeck R, Gerain J, Muller C, Klastersky J (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 7, 2013 Category: Respiratory Medicine Source Type: news

Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections
Wiley JM, Seibel NL, Walsh TJ (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - February 5, 2013 Category: Respiratory Medicine Source Type: news

Direct Healthcare Professional Communication: Interaction between sodium stibogluconate (Pentostam®) and amphotericin B deoxycholate
Source: MHRA Area: News GlaxoSmithKline has issued a Direct Healthcare Professional Communication regarding new interaction details for sodium stibogluconate (Pentostam®), which have been added to the product information.   An increased risk of fatal cardiac arrhythmias has been observed when amphotericin B deoxycholate is administered soon after sodium stibogluconate during retreatment of visceral leishmaniasis. Although the mechanism is unknown, it is suggested that sodium stibogluconate increases the susceptibility of the myocardium to damage by amphotericin B deoxycholate.   Sections 4.4 and 4.5 ...
Source: NeLM - News - February 4, 2013 Category: Drugs & Pharmacology Source Type: news

Empiric amphotericin B therapy in patients with acute leukemia
Holleran WM, Wilbur JR, DeGregorio MW (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - January 10, 2013 Category: Respiratory Medicine Source Type: news

Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients
Chopra R, Blair S, Strang J, Cervi P, Patterson KG, Goldstone AH (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - January 10, 2013 Category: Respiratory Medicine Source Type: news

Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients
Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA, Peters WP (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - January 10, 2013 Category: Respiratory Medicine Source Type: news

Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients
Jeffery GM, Beard ME, Ikram RB, Chua J, Allen JR, Heaton DC, Hart DN, Schousboe MI (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - January 10, 2013 Category: Respiratory Medicine Source Type: news

Clinical experience with amphotericin B in acute myelogenous leukemia
Stein RS, Greer JP, Ferrin W, Lenox R, Baer MR, Flexner JM (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - January 10, 2013 Category: Respiratory Medicine Source Type: news

Empiric therapy with amphotericin B in febrile granulocytopenic patients
Walsh TJ, Lee J, Lecciones J, Rubin M, Butler K, Francis P, Weinberger M, Roilides E, Marshall D, Gress J, et al (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - January 10, 2013 Category: Respiratory Medicine Source Type: news

Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex
Kline S, Larsen TA, Fieber L, Fishbach R, Greenwood M, Harris R, Kline MW, Tennican PO, Janoff EN (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - January 4, 2013 Category: Respiratory Medicine Source Type: news